Diagnostic And Prognostic Importance Of Gst, Its Isoenzymes And Tumour Marker In Breast Carcinoma

Abstract

Breast cancer is the second most prevalent cancer type after lung cancer (10.4 percent of all cancer incidence in both sexes) and the fifth most common cause of cancer death. Breast cancer can develop in any cell of the mammary gland and has a variety of behavioral traits, immunehistochemical profiles, and histological subtypes, each with its own course and clinic. Breast carcinomas are the most common lesions, but sarcomas and lymphomas of various types can be found. Screening measures such as mammography and breast examination, on the other hand, overlook 10–40 percent of early breast cancer cases. Recent advancements in monoclonal antibody technology have resulted in the discovery of tumor-specific monoclonal antibodies that have been marketed as potential tumor indicators. These antibodies don't recognize 'breast cancer-specific antigens,' but rather normal or mutated tissue antigens that are expressed preferentially or incorrectly on malignant cells. Many of these antigens can also be found in the serum of cancer patients. The role of CA 15-3 as a prognostic marker in breast cancer will be defined in this investigation.

AIM: Diagnostic and Prognostic Importance of GST, Its Isoenzymes and Tumour Marker in Breast Carcinoma

Need of Research: At present we have very few diagnostic tumor markers which can be used for diagnostic and prognostic purpose. Thus a combined use of all this markers will help us to increase accuracy in diagnosing and predicating patient’s health condition.